China-Singapore Jingwei, February 18 -- On the afternoon of the 18th, WuXi AppTec issued another clarification saying that WuXi AppTec has not, is and will not pose a risk to the United States in the past. WuXi AppTec also reiterated that it does not have a human genomics business.
WuXi AppTec's clarification announcement noted that the company noted that a U.S. congressman sent a letter to the U.S. Department of Commerce, the Treasury Department, and the U.S. Department of Defense on February 12, 2024, about the company. The company has always welcomed regulatory oversight of our industry and has successfully passed US** scrutiny on several occasions in the past. However, the Company strongly opposes misleading allegations, inaccurate determinations, and predetermined actions without due process against the Company.
WuXi AppTec emphasized that WuXi AppTec has not, is and will not pose a major risk to the United States in the past, and will not pose a major risk to the United States, and that the United States will come to the same conclusion even if the United States reviews the company again.
Screenshot of WuXi AppTec's announcement, the same below.
Subsequently, WuXi AppTec issued a "Further Announcement on Clarification Matters", stating that "Wuxi Apptec Co, ltd." is the English name of the company. "wuxi" or "wuxi" is not the name of the company, but the Chinese pinyin of the city "Wuxi". WuXi AppTec, a foreign-invested company registered in Wuxi, started its pharmaceutical R&D contract outsourcing (CRO) business more than 20 years ago.
WuXi AppTec reiterated that it does not have a human genomics business and that its existing businesses do not collect human genome data.
Previously, WuXi AppTec issued the "Clarification Announcement" and "Further Announcement on Clarification Matters" to A-share investors on January 26 and February 4 respectively. On January 26, January 30, February 4 and February 13, the "Voluntary Announcement" was issued to Hong Kong stock investors.
In the secondary market, WuXi AppTec's A and H shares have recently shown a downward upward trend. Specifically, on February 15 and 16, WuXi AppTec's H-shares rose twice in a row, closing at 40HK$80 shares; In terms of A-shares, before the Spring Festival in 2024, WuXi AppTec rose slightly after three consecutive gains, closing at 5312 yuan shares, the latest total market value of 156.9 billion yuan. (Zhongxin Jingwei app).
For more exciting content, please pay attention to the official WeChat of JWVIEW***